Journal
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1876, Issue 1, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.bbcan.2021.188577
Keywords
Platinum; Lung cancer; Therapy; Chemoresistance
Categories
Funding
- National Natural Science Foundation of China [82074069]
Ask authors/readers for more resources
Platinum resistance is a challenge in lung cancer treatment, and understanding its molecular mechanisms, identifying predictive markers, and developing more effective and less toxic agents are crucial. Addressing this issue could lead to the development of improved treatment for refractory lung cancer in the future.
Platinum compounds (cisplatin and carboplatin) represent the most active anticancer agents in clinical use both of lung cancer in mono-and combination therapies. However, platinum resistance limits its clinical application. It is necessary to understand the molecular mechanism of platinum resistance, identify predictive markers, and develop newer, more effective and less toxic agents to treat platinum resistance in lung cancer. Here, it summarizes the main molecular mechanisms associated with platinum resistance in lung cancer and the development of new approaches to tackle this clinically relevant problem. Moreover, it could lead to the development of more effective treatment for refractory lung cancer in future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available